AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION Page: 2 of

First Page		Document Content
Gadolinium Nephrogenic systemic fibrosis Gadodiamide Magnetic resonance imaging Pentetic acid Contrast medium Gadoteridol Gadoversetamide Schering AG Chemistry Matter Gadopentetic acid		AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION Page: 2 of Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 2,13 MB Share Document on Facebook

	OPTIMARK (gadoversetamide) injection Label DocID: KSKv - View Document
	AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION Page: 2 of DocID: D2qm - View Document
	Microsoft Word - GBCA Advisory Committee Meeting Briefing Document - Optimark - Errata.doc DocID: Cets - View Document
	OptiMARK™ 0.5 mmol/mL (Gadoversetamide Injection) PRESCRIBING INFORMATION Rx only Mallinckrodt Inc. May 2013 DocID: oanB - View Document
	May[removed]OptiMARK~ (gadoversetamide injection) For Intravenous Injection Only Mallinckrodt Inc. DocID: j2xA - View Document